Biomedical subjects

N G Pehrsson

Publications and source records attributed to N G Pehrsson.

6 recordsLinked to original sources

PubMed2001

Evaluation of a language-screening programme for 2.5-year-olds at Child Health Centres in Sweden.

UNLABELLED: A population-based language-screening programme started in the western part of Sweden (South Bohuslän) in 1991, with the aim of identifying developmental language disability in 2.5-y-old children. The programme was evaluated during 1998 in an experimental study. A group of 105 2.5-y-old children was recruited from 24 separate Child Health Centres. A sample of 25 children with a positive screening result was selected. For each of the 25 children, 1-4 controls, i.e. children with a negative screening result, were selected. The results were reclassified blindly by three speech and language therapists and used as a gold standard. Positive and negative predictive values were estimated to be 0.52 (95% confidence interval 0.31-0.72) and 0.96 (95% confidence interval 0.89-0.99), respectively. Baye's theorem was used to calculate the sensitivity (0.69) and the specificity (0.93) of the screening. A method of calculating the sensitivity and specificity of the test method by means of three samples was demonstrated. CONCLUSION: The data confirm that it is possible to identify reliably children with developmental language disability at 2.5 y of age through the screening programme.

Child↗

PubMed1996

[Short and long-term clinical tolerance of hypertensive treatment during the HOT study (Hypertension Optimal Treatment)].

International, prospective, randomized HOT study aims to determine the optimal BP level under treatment in order to reduce at the most the cardiovascular morbidity/mortality. Defined by randomization, the level to obtain is DBP < or = 80, 85, 90 mmHg. The treatment is started by felodipine 5 mg/day then, if necessary, a bitherapy is prescribed and then, if necessary, a tritherapy. 19,193 patients have been included (BP at randomization 170 +/- 15/105 +/- 4 mmHg). After 1 year treatment, it is possible to search for the influence on the clinical tolerance of sex, age, BP goal, geographic area, time and treatment. The percentage of patients with side effects by BP goals and by treatment type are, during the time and in different geographic areas, the following (NE/Northern Europe = Norway, Switzerland, Belgium, Hungary, Sweden, Denmark, Finland, The Netherlands, UK, Germany, Austria; SE/Southern Europe = Italy, Spain, Greece): [table: see text] The target BP and age don't nearly influence the clinical tolerance. The side effects reported by the physicians are more numerous at the treatment start than at longeur terme. That is due to the therapeutic modifications of the physicians or to a better acceptation of the drugs by the patients or to a real disappearance of the side effects. Reported side effects are more frequent in Southern Europe, France than Northern Europe and more frequent among women that men. The incidence of side effects is proportional to the number of prescribed drugs. Time and the number of antihypertensive drugs appear as the most important factors.

Age Factors↗

PubMed1977

Comparison between British Comparative Thromboplastin (BCT) and a factor II-VII-X determination method (simplastin A) based on fresh plasma samples from dicoumarol-treated patients.

Comparisons between British Comparative Thromboplastic (BCT) and a factor II-VII-X determination method--Simplastic A--have been carried out monthly during the time from December 1973 to March 1976. On each occasion fresh plasma from 20 dicoumarol-treated patients was analyzed with the two methods. It was found that the linear regression model is well suited for the comparison, that the BCT thromboplastin did not change significantly during the study, and that the method of comparing has a coefficient of variation of approximately 6-8%. This means, for instance, that a ratio of 3.8 with BCT corresponds to a ratio of 3.5 +/- 0.26 with Simplastin A. Thus in one period you may have ratio 3 and in another ratio 4 as the lower limit of the therapeutic range although you use the same thromboplastin and the same method. The importance of having a stable reference thromboplastin and an established method of comparing thromboplastins is stressed.

Blood Coagulation Tests↗

PubMed1977

Variations in blood coagulation, fibrinolysis, platelet function and various plasma proteins during the menstrual cycle.

The variations in the number of platelets, platelet retention, blood coagulation, fibrinolysis and various plasma proteins were studied during the menstrual cycle in 30 normal women. Blood samples were taken on 6 occasions; day 1, 2, and 3 of menstruation, day 5-9 (follicular phase), day 12-16 (around ovulation), and day 19-23 (luteal phase), respectively. The concentration of fibrinogen was lower during menstruation than in the luteal phase. Factor II-VII-X and platelet retention were lowest and the recalcification time was shortest during the menstruation. The number of platelets was highest in the ovulatory phase. The fibrinolytic activity was higher in the luteal phase and during the menstruation than in the follicular phase. The results might indicate an intrauterine clotting during the menstruation. The close correlations between the variations of most of the plasma proteins indicate the presence of some general not identified factor which is probably not the variation in the intravascular water content.

Adult↗

PubMed1977

Viability of the islets of Langerhans after warm ischemia as judged by isologous transplantation.

The influence of warm ischemia on pancreatic islet viability was studied by means of 63 isologous transplantations in adult AGUS rats. The pancreases were harvested 0, 20 and 40 min after circulatory arrest. The islets were isolated with collagenase and transplanted intra-portally in known numbers into streptozotocin-diabetic recipients. The islet-dose-metabolic-response relationships in three groups of recipients were compared. No significant difference was found in the quantitative yield. The smallest number of islets which reversed diabetes increased by 25% after a period of warm ischemia regardless of its duration.

Animals↗

PubMed1976

Blood coagulation, fibrinolysis and plasma proteins in women with normal and with excessive menstrual blood loss.

A group of women with excessive menstrual blood loss (menorrhagia) without any known local or general underlying disease was studied and compared to a group of women with normal menstrual blood loss. Blood coagulation, platelet function and fibrinolysis as well as a variety of plasma proteins were analyzed on six occasions during one menstrual cycle. Women with menorrhagia were found to have a slightly higher concentration of fibrinogen--fibrin degradation products, a higher factor V and VIII activity, higher antithrombin III, alpha 1-antitrypsin concentrations and higher antifibrinolytic activity than the normal women. The concentration of albumin, beta IE-globulin, orosomucoid, ceruloplasmin and IgG were lower in women with memorrhagia than in normals. The capillary fragility did not differ significantly between the groups. The observed differences in clotting factors between the groups could not have caused the differences in blood losses.

Adult↗